NCT04573777

Reducing Intracranial atheroSclErosis With Repatha

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of California, Los Angeles · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study will be to understand the underlying mechanism by which PCSK9 inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled almost 50,000 patients and showed that PCSK9 inhibition therapy is safe and effective. The investigators hypothesize that PCSK9 inhibition lowers the rate of stroke by reducing atherosclerotic plaque, which would be particularly beneficial for patients with intracranial atherosclerosis, who have the highest rate of recurrent stroke of any stroke mechanism.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Repatha	140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor

Timeline

• Start date: 2021-04-23
• Primary completion: 2021-12-16
• Completion: 2021-12-16
• First posted: 2020-10-05
• Last updated: 2023-03-15
• Results posted: 2023-03-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study